Icatibant Cipla

Icatibant, the active ingredient in Icatibant Cipla, is a bradykinin B2 receptor antagonist presented as a subcutaneous formulation for injection use. It is indicated for the treatment of acute attacks of hereditary angioedema in patients with C1‑inhibitor deficiency. GNH USA supplies Icatibant Cipla as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Icatibant is a targeted therapy for the bradykinin‑mediated pathway that underlies hereditary angioedema. - Acute hereditary angioedema (C1‑inhibitor deficiency): rapidly reduces swelling and restores airway patency during an attack. - Hereditary angioedema type I: provides symptom relief by blocking excess bradykinin. - Hereditary angioedema type II: mitigates edema by antagonizing the B2 receptor.

Icatibant may cause a range of adverse reactions, most of which are related to its subcutaneous administration and pharmacologic activity.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the injection site. - Redness or erythema: localized skin reddening. - Swelling at injection site: transient edema. - Nausea: occasional gastrointestinal upset. - Headache: mild to moderate intensity. - Dizziness: transient light‑headedness.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Angioedema: paradoxical swelling in other body regions. - Severe hypotension: marked drop in blood pressure. - Urticaria: widespread hives. - Thrombocytopenia: low platelet count. - Severe injection site infection: signs of cellulitis or abscess.

Before using Icatibant, clinicians should consider several safety aspects to minimise risk. - Contraindication: known hypersensitivity to icatibant or any excipients. - Pregnancy: safety not established; use only if clearly needed. - Breastfeeding: unknown; weigh benefits against potential risks. - Renal or hepatic impairment: monitor closely as clearance may be affected. - Concomitant bradykinin‑enhancing drugs: avoid or adjust therapy. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Icatibant can interact with other medicines that influence the bradykinin system or vascular tone.

Major Interactions (Avoid): - ACE inhibitors: may increase bradykinin levels and exacerbate angioedema. - Neprilysin inhibitors: elevate bradykinin, raising risk of severe swelling. - Other bradykinin B2 antagonists: additive pharmacologic effect.

Moderate Interactions (Monitor Closely): - Estrogen‑containing oral contraceptives: may modestly increase bradykinin activity. - Hormone replacement therapy: similar potential effect. - Diuretics: monitor blood pressure changes. - Antihistamines: may mask early signs of allergic reactions. - NSAIDs: watch for increased risk of edema.